The cluster is directionally bullish but small in absolute dollars for a biotech micro-cap. Monitor upcoming pipeline catalysts (clinical trial readouts, regulatory updates) that may validate the accumulation thesis.
Executive Summary
Seven institutional investors accumulated $4.2M net in Verastem (VSTM) in Q3 2024, led by Alyeska Investment Group more than doubling its position to $5.6M, while Citadel nearly exited. The strong buy-side conviction from multiple active managers suggests a shared thesis on the clinical pipeline, but the small absolute dollar amounts and the company's history of stock declines warrant cautious interpretation.
Key Financial Metrics
Institutional Positions
Net institutional flow: $4.2M
▲ Buyers (7)
| Institution | Action | Change | Position Value | Value Δ |
|---|---|---|---|---|
| Alyeska Investment Group | DOUBLED | +165.7% | $5.6M | $3.5M |
| Walleye Capital | DOUBLED | +493.7% | $646.0K | $538.0K |
| Stifel Financial | ADD | +62.3% | $91.0K | $35.0K |
| Legal & General Group | ADD | +71.7% | $14.0K | $6.0K |
| Schwab | ADD | +46.3% | $310.0K | $99.0K |
▼ Sellers (1)
| Institution | Action | Change | Prev Value | Value Δ |
|---|---|---|---|---|
| Citadel | NEAR_EXIT | -90.4% | $91.0K | -$81.8K |
Key Facts
- 7 buyers accumulated net $4.2M in VSTM during Q3 2024 (current holdings $6.7M), versus 1 seller reducing by $82K
- Alyeska Investment Group more than doubled its stake, adding $3.5M (current value $5.6M), representing ~84% of total buying activity
- Walleye Capital nearly quintupled its shares (+493.7%), adding $538K
- Citadel reduced its position by 90.4%, exiting nearly completely with remaining $9K
Financial Impact
Net institutional accumulation of $4.2M (total buyer current holdings $6.7M) across 7 funds, with one seller reducing by $82K. The largest move came from Alyeska Investment Group adding $3.5M.
Risk Factors
- Small dollar amounts ($6.7M total) limit the signal's market impact
- 13F data is 45+ days stale; positions may have already been adjusted
- Clinical-stage biotech risk: single trial failure could erase value regardless of ownership changes
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 institutional 13F filing from SEC EDGAR.
| Document | Accession Number |
|---|---|
| INST-CLUSTER Data (Synthetic) | inst-cluster-VSTM-2024-Q3 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 14, 2026 12d ago | 8-K | $9.23 | awaiting T+60 | — | — |
Oct 14, 2026 12d ago | 424B5 | $9.23 | awaiting T+60 | — | — |
Oct 14, 2026 12d ago | 424B5 | $9.23 | awaiting T+60 | — | — |
Oct 14, 2026 13d ago | 8-K | $7.71 | awaiting T+60 | — | — |
Oct 2, 2026 24d ago | Insider Cluster | $8.00 | awaiting T+60 | — | — |
Jun 23, 2026 17w ago | 8-K | $3.85 $7.55 | ▲ +96.10% | ▲ +93.27% | — |
Jun 17, 2026 18w ago | 8-K | $4.17 $7.32 | ▲ +75.54% | ▲ +72.39% | — |
Jun 11, 2026 19w ago | Institutional Cluster | $4.10 $8.08 | ▲ +97.07% | ▲ +93.81% | — |
Jun 11, 2026 19w ago | Institutional Cluster | $3.94 $8.20 | ▲ +108.12% | ▲ +103.73% | — |
May 27, 2026 21w ago | 3 | $4.29 $6.89 | ▲ +60.61% | ▲ +58.87% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers